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IN addition  to  its  well-established  effect  on  T  cells,
cyclosporin A (CsA) also inhibits inflammatory cyto-
kine production by macrophages.  However, little is
known  about  the  mechanism  of  action  of  CsA  on
macrophage cytokine production. We measured the
effect of CsA on basal and phorbol-myristate-acetate
(PMA)-stimulated  production  of  interleukin-6  using
the  human  monocyte  cell  line  U937  differentiated
with dimethylsulfoxide (DMSO). Interleukin-6 levels
were measured in supernatant and cell lysates using
specific  enzyme-linked  immunosorbent  assays.  We
found that CsA decreases not only IL-6 release but also
cytokine synthesis. The concentration of CsA used did
not affect either cell viability or proliferation. Three
possibilities may be advanced to explain the CsA-due
decrease  in  IL-6  production  by  macrophages:  (a)
inhibition  of  the  synthesis  of  an  early  common
regulatory  protein,  (b)  inhibition  of  cytokine  gene
transcription,  or  (c)  modulation  of  post-transcrip-
tional  events.  The  first  possibility  was  tested  by
measuring the effect of cycloheximide on the experi-
mental  system  during  the  first  3  hours  of  culture.
Although  cycloheximide  decreased  total  cytokine
synthesis, the pattern of cytokine modulation by CsA
persisted. These data suggest that CsA-mediated mac-
rophage  cytokine  inhibition  is  not  mediated  by  an
early common regulatory protein. To further explore
the inhibition mechanism, we measured IL-6 mRNA
levels  by  Northern  blot.  IL-6  mRNA  levels  were
unaffected by CsA both in resting and PMA-stimulated
cells. We conclude that in human macrophages CsA
diminishes  IL-6  production  at  post-transcriptional
level.
Key  words:  Cyclosporin  A,  Interleukin-6,  Macrophage,
U937.
Introduction
Cyclosporin A  (CsA)  is  an  immunomodulatory  sub-
stance used in the prevention of transplant rejection
and in the treatment of autoimmune disease.1 Class-
ically, CsA has been reported to exert its immunomo-
dulatory action through its effect on T lymphocytes,
mainly  helper  T  lymphocytes,  by  inhibiting  calci-
neurin dependent interleukin-2 synthesis.2,3 Recently,
however, it has been suggested that the inhibition of
T  lymphocyte  activation  by  CsA  does  not  appro-
priately account for all the effects observed following
in  vivo administration  of  the  drug.4 Accordingly,
despite  widespread  use  of  the  drug,  the  specific
mechanism  of  action  of  CsA  remains  to  be  fully
elucidated.5 It is also possible that its effects could be
due in part to the action of CsA on other cells.6 In this
sense, it should be noted that CsA binds specifically,
reversibly and  in  a  time-and  temperature-dependent
fashion  to all  human  leucocytes.  However, granulo-
cytes and cells of the mononuclear phagocyte system
(MPS) sometimes bind more CsA than lymphocytes,
probably because the drug is rapidly internalized.2,7
Cells  of  the MPS  offer  an  attractive  possibility  to
study the effects of this drug because they participate
in  a  crucial  manner in  antigen  presentation  and,  in
many  cases,  are  the  final  effectors  of  the  immune
system. Many references in the literature report the
capacity of CsA to alter the activities of MPS cells. In
general,  the  capacities,  functions  and  actions  of
macrophages related to non-specific defense such as
chemotaxis, phagocytosis, enzyme release and respi-
ratory  burst,  can  be  said  to  be  more  resistant  to
CsA.8,9 By contrast, those related to  immunoregula-
tion  or  accessory  functions,  such  as  monokine
production, the expression of histocompatibility anti-
gens and antigen presentation,  are more susceptible
to the action of CsA.8,9
Macrophages synthesize and secrete IL-1b , TNF-a ,
IL-6 and IL-8.10 These monokines are known  media-
tors of the inflammatory response10 and are therefore
also  known  as inflammatory  cytokines.  It  has been
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Mediators of Inflammation, 8, 253–259 (1999)reported  that  CsA  inhibits  the  production  of IL-1b ,
TNF-a and  IL-6  in  different  cells  of  the  MPS.11,12
However, the mechanism through which this occurs
is not well known.13
In the light of the foregoing, the aim of the present
study was to evaluate and determine the mechanism
of action of CsA on the production of interleukin-6 by
macrophages.  To  do  so,  the  human  differentiated
U937 monocyte line was employed.
Methods
Cell line
U937 cells were kindly  supplied by Dr J.  Olmos of
the  Hospital  Universitario  Marqu´ es  de  Valdecilla,
Santander (Spain). The cell line was kept at 37°C in
a  humidified  atmosphere  with  5%  CO2 in  culture
with  complete  medium  containing  RPMI  1640
(Sigma®),  100U/mL  of  penicillin  (Sigma®),
100U/mL  of  streptomycine  (Sigma®),  2 mM
L-glutamine (Sigma®) and 10% fetal calf serum (FCS)
(Gibco®)  in  sterile  culture  flasks  (Nunclon®)  at  a
concentration  between  0.75  3 105 and  5  3 105
cells/mL. Cell viability was greater than 90% and the
duplication  time  was  between  24  and  48  hours.
Cells were regularly screened for lipopolysaccharide
(LPS),  bacteria,  mycoplasma  and  fungal  contamina-
tion  and  found  to  be  negative.  Cells  were  differ-
entiated by culture over 4 days in complete medium
containing  1.3%  dimethylsulfoxide (DMSO).
Cell cultures
5 3 105 cells together with different stimuli and/or
CsA  at  the  following  concentration  were  added  to
each  well  of  the  culture  dishes  (Costar®)  with
complete  medium:  Lipopolysaccharide  from  E.  coli
(Sigma®)  at  100 m g/mL  and  10 m g/mL;  phorbol-
12-myristate-13-acetate  (PMA)  (Sigma®)  at  10–4M
and  10–5M;  human  gamma-interferon  (Sigma®)  at
1000U/mL  and  100U/mL  and  CsA  (Sandoz®)  at
three non-toxic concentrations in vivo: 200, 20 and
2 ng/mL.
Cells were kept at 37°C in a humified atmosphere
with  5%  CO2 for  18  hours,  after  which  the  super-
natants  were  centrifuged  at  500g  for  10min  to
sediment cells in suspension and then stored at –70°C
until later determination.
After the supernatant had been removed, 400 m L of
a 0.25M sucrose–0.02 EDTA solution was added to
each well. After  the bottom of each well had  been
scraped  vigorously,  the  content  was  aspirated  and
added to the previous cell pellet, thus recovering all
the  cells.  The  cells  were  then  subjected  to  heat
disintegration by repeated freezing–thawing (6 cycles
of  10min  freezing  and  15min  thawing)  and  were
stored at –70°C until determination.
To study  the inhibition of early protein synthesis,
cycloheximide (Sigma®) at a concentration of 1 m g/mL
was added during the first 3 hours of cell culture.
Cytokine determination
The inflammatory cytokine IL-6 was determined by
direct  double-sandwich  enzyme-linked  immunosor-
bent assay (ELISA) of antibodies in the supernatants
and cell lysates. BIOTRAK® (Amersham, UK) commer-
cial kit specific for human IL-6 was used; this showed
no  cross-reactivity  with  other  cytokines.  It  had  a
coefficient of variation less than 10%, and a sensitivity
limit  of  0.35pg/mL. All  samples  were  measured  in
duplicate. Results were expressed in picograms/106
cells. It should be noted that in ELISA assays none of
the components of the culture medium (RPMI 1640,
antibiotics,  glutamine  or  fetal  calf  serum)  showed
immunoreactivity with the cytokine studied.
IL-6 mRNA expression
Transcription of the IL-6 gene was studied by North-
ern  blot. Differentiated U937 cytoplasmic RNA was
isolated by 150mM NaCI, 1mM MgCI2, 10mM Tris-
HCI pH 7.4, 0.5% Nonidet P40 and 250–1000U/mL
RNAsing (Promega®) lysis, followed by two succes-
sive  ultracentrifugations  with  Tris-buffered  phenol
and  10%  SDS  and  phenol,  respectively.  RNA  was
precipitated  overnight  with  cold  ethanol  and  3M
sodium acetate pH 7.2, and redissolved in Tris-EDTA
pH  7  buffer.  RNA  was  quantified  by  determining
optical  density  at  a  wavelength  of  260nm.  The
quality  of the RNA was checked by the demonstra-
tion of two bands corresponding to ribosomal RNA
(18s and 28s) and the absence of degradation of the
RNA  by  staining  with  ethidium  bromide  in  the
electrophoresis of a 1% agarose minigel loaded with
1.5 m g  of  RNA.
RNA was denatured by incubation for 1 h at 50°C
in a solution of 1 M glyoxal, 50% DMSO and 10mM
NaH2PO4. Following this, 5 m g of RNA  were mixed
with  electrophoresis  sample  buffer  (50%  glycerol,
49.6% 10mM NaH2PO4 pH  7.0, 0.4% bromophenol
blue). After  loading  samples,  electrophoresis  (35V)
was carried out in 1% agarose-10mM NaH2PO4pH 7
gels  using  10mM  NaH2PO4pH  7  buffer.  Following
electrophoresis,  the  RNA  was  transferred  overnight
by capillarity  from the gel to  a nitrocellulose mem-
brane  using  203 SSC.  This  membrane  was  dried
with Whatman  paper and the RNA was cross-linked
to the membrane by exposure to UV light. Then, the
membrane  was  prehybridized  for  2 h  at  65°C  in  a
solution containing 6.4% dextran,  33 SSC, 13 Den-
hart’s,  0.1%  SDS  and  250 m g/mL  heat-denatured
salmon  sperm  DNA.  IL-6  cDNA  and  G3PDH  cDNA
probes  commercialized  by  the American Type  Cul-
ture Collection (ATCC) were labelled with 32P using
J. E. Losa Garc´ õa et al.
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tech®)  following  the  protocol  indicated  by  the
manufacturer. Hybridization (18h, 65°C) was carried
out  using  the  same  prehybridization  solution  con-
taining heat-denatured 32P-labelled probes. Following
successive  washings  in  0.1  SDS-0,  1  SSC  at  room
temperature  and  65°C,  respectively,  membranes
were blotted dry and used for autoradiography with
XR  film  (Cronex  105,  Dupont®)  at  –70°C  over  6
days. Hybridization with the G3PDH probe was used
as an  RNA  loading control  for  blots.
Results
Differentiation of the U937 line
The data (not shown) confirming that suitable differ-
entiation  of  the  monocyte  cell  line  toward  macro-
phage cells had been achieved were as follows:
d a decrease in the cellular proliferation rate without
viability being affected;
d an increase in adherence to the culture supports
and among cells;
d an  increased  cytoplasm,  the  disappearance  of
nuclear  polylobulation  and  a  decrease in  nuclear
atypias and the number of nucleoli;
d an increase in the content of macrophage enzymes
(non-specific esterases); and
d an increase in cytoplasmic RNA content.
Determination of type of stimulus and most
effective concentration on interleukin-6
secretion
In order to study the most suitable type of stimulus for
inducing the secretion of IL-6 and the most effective
concentration,  U937  cells  were  used  under  both
differentiated and undifferentiated conditions. Three
classic stimuli were studied at two different concen-
trations: lipopolysaccharide (LPS), phorbol myristate
acetate  (PMA)  and  gamma-interferon  (g -IFN).  The
mean values of the results of the study carried out in
quadruplicate are shown in Fig. 1. Overall, the data
obtained  indicate  that  the  most  potent  stimulus  of
cytokine  secretion  was  PMA  at  a  concentration  of
10–5M.  IL-6  secretion  was  greater  by  differentiated
U937 cells than by undifferentiated ones.
Effect of CsA on the synthesis of interleukin-6
The results of the effect of different concentrations of
CsA on IL-6 secretion under both basal and stimulated
conditions are shown in Table 1. These data show the
mean values obtained in four different assays. As may
be  seen, both in  undifferentiated  and  differentiated
U937 cells, at the highest concentration used (200ng/
mL) CsA decreased stimulated secretion of IL-6. CsA
can be said to decrease the secretion of this cytokine
more  than  50%.  The  effect  of  CsA  on  basal  IL-6
secretion was much lower.
Cyclosporin and macrophage IL-6 synthesis
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FIG. 1. Effect of different stimuli on IL-6 secretion by U937 cells. The most potent stimulus of cytokine secretion was PMA at
a concentration of 10
–5M. Definition of abbreviations: IFN, interferon; IL-6, interleukin-6; LPS, lipolysaccharide; PMA, phorbol
myristate acetate. Note the logaritmic scale.Using U937 cells differentiated with  1.3% DMSO,
the intracellular  content  of IL-6 was measured after
stimulation  with  phorbol myristate in  two different
assays. At 200ng/mL, CsA decreased the intracellular
content of IL-6 from 151,0 ± 97,2 to 100,0 ± 61,3pg/
106 cells.  So,  CsA  can  be  said  to  decrease  the
production  of  cytokines  since  both  the  intra-and
extracellular contents were affected.
Effect of CsA on cell viability and cell
proliferation capacity
The first and simplest possibility considered was that
CsA would affect cell viability and/or proliferation and
hence  that  the  decrease  in  cytokine  production
would  be  due  to  a  decrease  in  these  capacities.
Accordingly,  a  duplicate  study  was  performed  in
which the proliferation capacity and cell viability of a
U937 line subjected to the same stimuli as those used
in the study were evaluated. Table 2 shows the results
of this study.
As  seen,  CsA  did  not  affect  either  viability  or
proliferation capacity, either in undifferentiated U937
cells or in cells differentiated with DMSO. Therefore
the  results  on  cytokine  secretion  cannot  be  inter-
preted in these terms.
In  this  study,  the  effects  of  several  stimulatory
substances were also assessed. Both PMA and LPS, but
not  gamma-interferon,  were  seen  to  decrease  cell
viability.
Effect of cycloheximide on CsA inhibition of
IL-6 production
To study the mechanism by which CsA decreases IL-6
production,  three  working  hypotheses  were
addressed: that CsA affects the synthesis of an early
protein,  responsible  for the decreased  levels of the
cytokine;  that  it  exerts  its  action  at  transcriptional
level, and that its effect is mediated at post-transcrip-
tional level.
The  first  mechanism  proposed  was  evaluated  by
treatment with cycloheximide (an inhibitor of protein
synthesis) of differentiated U937 cells during the first
3  hours  of  culture.  Prior  to  this  study  it  was
ascertained  that  cycloheximide  does  not  affect  cell
viability (data not shown).
The effect of cycloheximide on the secretion of IL-6
is detailed in Fig. 2. As may be seen, although overall
this drug decreased both basal and stimulated cyto-
kine  secretion  in  differentiated  cells,  which  was
expected, the inhibitory effect of CsA persisted in all
cases. It is therefore unlikely that the mechanism of
action  of  CsA  would  depend  on  inhibition  of  the
synthesis of an early protein.
Effect of CsA on expression of the IL-6 gene
Study of the action of CsA on the expression of IL-6
mRNA  by  Northern  blot  was  carried  out  on  the
differentiated  cell  line  under  both  basal  and  stimu-
lated conditions. Two assays were performed and, in
each, Northern  blot was implemented in  duplicate.
Figure 3 shows the results of one of the assays. As may
be seen, CsA did not affect the levels of IL-6 mRNA
under either basal or stimulated conditions.
J. E. Losa Garc´ õa et al.
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Table 1. Effect of CsA on basal and stimulated IL-6 secretion
by  U937  cells  (pg/10
6 cells).  Both  in  undifferentiated and
differentiated U937 cells, at the highest concentration used
(200  ng/mL)  CsA  decreased  stimulated  secretion  of  IL-6.
Definition of abbreviations: CsA, cyclosporin A; PMA, phor-
bol myristate acetate; SEM, standard error of mean.
Mean SEM
Undifferentiated
Basal 38,4 7,9
+ CsA (2ng mL
–1) 37,6 13,1
+ CsA (20ng mL
–1) 34,0 12,7
+ CsA (200ng mL
–1) 25,2 4,2
+ PMA 10
–5 M 1705,1 313,5
+ CsA (200ng mL
–1) 731,4 66,0
DMSO differentiated
Basal 90,4 27,6
+ CsA (2ng mL
–1) 99,7 33,3
+ CsA (20ng mL
–1) 91,4 34,2
+ CsA (200ng mL
–1) 67,1 20,6
+ PMA 10
–5 M 6343,7 3135,6
+ CsA (200ng mL
–1) 2035,1 1072,6
Table 2. Effect of CsA and different stimuli on cell proliferation and viability. In this study we started out with a viable cell
concentration of 250,000/mL, obtaining the data after 18 hours of culture. CsA did not affect either the viability or proliferation
capacity of either differentiated or undifferentiated cells. Additionally, both LPS and PMA, but not interferon, decreased cell
viability. Definition of abbreviations: CsA, cyclosporin A; LPS, lipopolysaccharide; PMA, phorbol myristate acetate
Undifferentiated U937 cell line
Viable cells/mL Viability (%)
Differentiated U937 cell line
Viable cells/mL Viability (%)
Basal conditions 370.000 91 317.000 95
PMA 10
–5 M 240.000 84 128.000 76
LPS (100m g/mL) 335.000 88 280.000 88
g -Interferon (1000U/mL) 400.000 94 285.000 92
CsA (200ng/ML) 385.000 94 300.000 93
CsA (200ng/mL) + PMA 10
–5 M 240.000 77 115.000 81Discussion
Differentiation of the U937 cell line
Study of the mechanism of action of CsA on inflamma-
tory  cytokine  production  by  human  macrophages
could have been  carried out  in  tissue macrophages
obtained  ex  vivo.  However,  the  limited  number  of
cells available for the different experiments, together
with  the  difficulty  involved  in  obtaining  healthy
control cells, within-group variability and, above all,
the influence of the action of the drug on other cells
–  especially  lymphocytes  –  counselled  against  this.
Therefore, to study the mechanism of action of CsA
on cytokine production in macrophages and to have
available a sufficient number of cells, the possibility of
using a monocyte cell line – namely, U937 cells – was
implemented. This  had  the  additional  advantage  of
enabling study of a completely pure population; that
is,  completely  excluding  the  presence  of  lympho-
cytes,  which  might  alter  the  results  obtained. The
literature contains references to use of the U937 cell
line in the evaluation of different macrophage func-
tions.14 This human  cell line grows continuously in
suspension and was initially  obtained from a pleural
effusion in a patient with histiocytic lymphoma.15 Its
phenotype corresponds to immature monocyte cells
arrested in a differentiation state close to the myelo-
monocytic  stem  cell.15 It  should  be  recalled  that
macrophages are highly differentiated cells and there-
fore have low proliferation capacity while cell lines
show a strong duplication rate. Thus, the first step in
this part of the work was to differentiate the human
U937 monocyte cell line.
In  the presence  of  several  substances  U937 cells
undergo  a  process  of  differentiation  and  therefore
acquire morphological and functional characteristics
similar to those of macrophages.16 Since one of the
interests in the present work was to study the effect
of PMA on cytokine secretion, DMSO was chosen as a
Cyclosporin and macrophage IL-6 synthesis
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FIG. 2. Effect of cycloheximide on the action of CsA in U937
cells. The effect of cycloheximide was evaluated in differ-
entiated  cells.  Although  overall  cycloheximide  decreased
both basal and stimulated cytokine secretion, the inhibitory
effect of CsA persisted in all cases. Definition of abbrevia-
tions; CsA, cyclosporin A; IL-6, interleukin-6; PMA, phorbol
myristate acetate.
FIG. 3. Effect of CsA on IL-6 mRNA expression. Study of the action of CsA on IL-6 mRNA expression by Northern blot was
carried out on the differentiated cell line under both basal and stimulated conditions. As seen, CsA did not affect IL-6 mRNA
levels under either basal or stimulated conditions. Definition of abbreviations: CsA, cyclosporin A; GPDH, glyceraldehyde
phosphate dehydrogenase; IL-6 interleukin-6; PMA, phorbol myristate acetate.differentiating agent because it displays differentiating
capacity on the U937 cell line.17 Differentiation  was
evaluated  by  kinetic,  morphological,  cytochemical
and  molecular  techniques.  The  results  obtained,
which  were  similar  to  those  reported  by  other
authors,15,17 allowed us to conclude that the protocol
used is indeed able to differentiate this cell line.
Choice of cellular stimulus
DMSO-differentiated U937 cells retain their capacity
to  be  stimulated  later  on  with  different  agents,17
among  them  PMA.18 It  should  be  noted  here  that
differentiation  and  activation  are  not  incompatible
concepts  and  that  it  is  in  fact  possible  to  employ
several  substances16 to  activate  cells  differentiated
with other agents. Here, we evaluated the effect of
three  known  macrophage  stimulating  agents  and
observed  that  for  this  purpose  the  most  suitable
agent  was  PMA  at  a  concentration  of  10–5 M.
Although  according  to  the  literature  lower  concen-
trations  of  this  substance  are  usually  used,15,17 in
each  experimental  system  it  is  necessary  to  obtain
evidence of the most effective concentration in the
induction of a given effect. Therefore in the present
study  the  aforementioned  concentration  was  used.
Although at this concentration PMA directly decrea-
ses  cellular  viability,  from  a  quantitative  point  of
view the increase that  it  induces in  cytokine secre-
tion  cannot  be  attributed  to  the  elimination  of
cytokines by dead cells.
Production of interleukin-6 by U937 cells
Once the required experimental conditions had been
established, IL-6 secretion by U937 cells was studied.
The  secretion  of  IL-6  was stronger  in  differentiated
than  in  undifferentiated  cells.  Recently  it  has  been
reported  that  the  CD419 and  CD2320 surface  mole-
cules present in differentiated MPS cells are involved
in the secretion of IL-6 by U937 cells. Although none
of  them  used  a  protocol  identical  to  the  one  used
here, different studies have documented the produc-
tion of different inflammatory cytokines by these cells
using  bioassays,21 immunoassays22–25 or  molecular
biology techniques.21,24 Hass et al.22 did not detect IL-
6  secretion,  possibly  due  to  the  stimulation  condi-
tions, and the values described by Jiang et al.23 for IL-
6  are  lower  than  our  own,  although  they  used
different protocols.
Effect of CsA on interleukin-6 production
Both  in  undifferentiated  and  differentiated  U937
cells,  at  the  highest  concentration  used  used
(200ng/mL)  CsA  decreased  stimulated  secretion  of
IL-6, more than 50%, a value similar to that reported
by  Moutbarrik  et  al.26 In  human  monocytes  at
therapeutic concentrations in vivo. Additionally, CsA
decreased  the  intracellular  concentration  of  IL-6.
Accordingly, in the differentiated U937 cell line CsA
can be said to decrease the production of inflamma-
tory cytokines. The effect of CsA  on  the U937 cell
line  is  not  well  documented.  In  a  review  of  the
literature  no  references  to  these  phenomena  were
found.
Mechanism of action of CsA on the production
of interleukin-6
From the theoretical point of view, the effect of CsA
on the production of interleukin-6 could be due to a
decrease in cell viability and proliferation and hence
to a decrease in the number of producing cells, to the
alteration of an early protein that would regulate the
gene expression  of cytokines, to  a  direct action  on
gene  transcription,  or  to  a  modification  of  post-
transcriptional events.
The data obtained here allow us to exclude a direct
effect of CsA on cell proliferation and viability. We can
also exclude its action at early level since incubation
with cycloheximide during the first hours of incuba-
tion did not affect the inhibitory effect of CsA. The
expected decrease in IL-6 production by U937 cells
due to the action of cycloheximide is consistent with
the observations of other authors27 who have repor-
ted  that  this  drug  inhibits  stimulation  of  IL-1b
synthesis in the U937 cell line.
Finally, this immunomodulator does not alter IL-6
mRNA expression, allowing us to conclude that the
effect  of  CsA  on  IL-6  production  occurs  at  post-
transcriptional level. Results similar to those obtained
by  us  have  been  published  by  Kato  et  al.28 who
observed that CsA scarcely affects the expression of
the IL-6 gene in human peripheral blood monocytes.
Likewise,  in  a  murine  mast  cell  line  Nair  et  al.29
reported that CsA does not alter IL-6 mRNA expres-
sion although it does affect IL-3 mRNA. It would thus
appear that in the human MPS CsA has little effect on
the transcription of monokine genes since the mRNA
levels of IL-1,30 TNF30 and IL-831 are not affected by
CsA either.
The  exact  mechanism  by  which  CsA  exerts  its
effect on cells of the MPS is not known although it has
been suggested that its effect could be related to an
inhibition  of  protein  secretion/synthesis.32,33 If,  as
commented  earlier,  it  is  true  that  CsA  inhibits  the
secretion  of  inflammatory  cytokines  and  does  not
affect  the  transcription  of  their  genes,  its  action
would appear to occur at post-transcriptional level.
In view of the decrease in immunogenic protein,
CsA  may  act  at  some  step  between  mRNA  and
synthesis of the protein. Although this aspect was not
studied explicitly in the present work, the idea that
CsA might act on intracellular membranes involved in
protein synthesis could be entertained. At least three
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for this. First, one could be dealing with a non-specific
interaction,  owing  to  the  lipophilic  nature  of  this
immunomodulator. In this sense, it has been demon-
strated  that  other  lipophilic  substances  or  lipid
emulsions are able to inhibit cytokine production by
macrophages  through  this  mechanism.34 Second,
although  there  is  no  consensus  about  the  possibil-
ity,35,36 CsA might inhibit protein kinase C activity in
macrophages. Thus, it has recently been observed that
inhibition of this enzyme decreases TNF-a production
in  LPS-stimulated  macrophages.37 Finally,  another
possibility would be that one would be dealing with a
specific  action  derived from  the interaction  of  CsA
with  cytokines  associated  with  intracellular  mem-
branes.38 Further  studies  are  evidently  required  to
clarify all these aspects.
It should be noted that some authors have situated
the site of action of CsA on monokine secretion at the
level of release since they observed a decrease in the
secretion of TNF-a with normal expression of the gene
and  normal  intracellular  cytokine  synthesis.13 How-
ever, these studies were carried out in mouse MPS cells
while those used here were from a human source.
Accordingly,  it  may  be  concluded  that  at  ther-
apeutic  and  non-toxic  concentrations  in  vivo,  CsA
decreases the production of interleukin-6 by human
macrophages at post-transcriptional level.
References
1. Fathman CG, Myers BD. Cyclosporine therapy for autoimmune disease. N
Engl J Med 1992; 326: 1693–1695.
2. Hess  AD,  Colombani  PM,  Esa  AH.  Cyclosporine  and  the  immune
response: basic aspects. Crit Rev Immunol 1986; 6: 123–149.
3. Schreiber SL, Crabtree GR. The mechanisnm of action of cyclosporin A
and FK506. Immunol Today 1992; 13: 136–142.
4. Ren K, Van  Liew JB,  Noble B. The effect  of cyclosporin A on disease
progression in proliferative immune complex glomerulonephritis. Clin
Immunol Immunopathol 1993; 66: 107–113.
5. Hess AD. Mechanisms of action of cyclosporine: considerations for the
treatment of autoimmune diseases. Clin Immunol Immunopathol 1993;
68: 220–228.
6. Chapman I, Mazzoni L. Mechanisms of inhibition by cyclosporin A on
pulmonary leukocyte  accumulation. Trends  Pharmacol  Sci 1994; 15:
99–101.
7. Ryffel B, Willard-Gallo  KE, Tammi  K,  Loken MR. Quantitative fluores-
cence  analysis  of  cyclosporine  binding  to  human  leukocytes.  Trans-
plantation 1984; 37: 276–280.
8. Mrowietz  U,  Christophers  E.  Effects  of  cyclosporine A  treatment  on
psoriasis. I:  Influence  of  low-dose cyclosporine  on human  monocyte
function in vitro. Transplant Proc 1988; 20(Suppl 4): 53–57.
9. Losa  JE,  Mateos  F,  Jim´ enez A,  P´ erez  JL. Action  of  cyclosporin A  on
mononuclear  phagocytes.  J  Invest  Allergol  Clin  Immunol 1996;  6:
222–231.
10. Losa JE, Mateos F , Mart´ õn MR, et al. Evaluation of inflammatory cytokine
secretion by human alveolar  macrophages. Mediat Inflamm 1999; 8:
43–51.
11. Tipton  DA,  Pabst  MJ,  Dabbous  MK.  Interleukin-1  beta-  and  tumor
necrosis  factor-alpha-independent  monocyte  stimulation  of  fibroblast
collagenase activity. J Cell Biochem 1990; 44: 253–264.
12. Rofe AM, Philcox JC, Haynes DR, Whitehouse MW, Coyle P . Changes in
plasma  zinc,  copper,  iron,  and  hepatic  metallothionein  in  adjuvant-
induced arthritis treated with cyclosporin. Biol Trace Elem Res 1992; 34:
237–248.
13. Nguyen DT, Eskandai MK, DeForge LE, et al. Cyclosporin a modulation of
tumor necrosis factor gene expression and effects in vitro and in vivo. J
Immunol 1990; 144: 3822–3828.
14. Keicho N, Sawada S, Kitamura K, Yotsumoto H, Takaku F. Effects of an
immuno-suppressant,  FK506,  on  interleukin  1  alpha  production  by
human  macrophages  and  a  macrophage-like  cell  line,  U937.  Cell
Immunol 1991; 132: 285–294.
15. Minta  JO,  Pambrun  L.  In  vitro  induction  of  cytologic  and  functional
differentiation of the immature human monocytelike cell line U-937 with
phorbol myristate acetate. Am J Pathol 1985; 119: 111–126.
16. ¨ Oberg F, Botling J, Nilsson K. Macrophages and the cytokine network.
Transplant Proc 1993; 25: 2044–2047.
17. Sakano T , Fujie A, Hamasaki T, Harada Y, Taniguchi H, Ueda K. Intracellular
Ca2+  mobilization  in  immature  and  more  mature  U937  induced  to
differentiate by  dimethyl  sulfoxide  or  phorbol  myristate  acetate.  Cell
Immunol 1988; 111: 390–397.
18. Rzigalinski BA, Rosenthal MD. Effects of DMSO-induced differentiation
on arachidonate mobilization in the human histiocytic lymphoma  cell
line U937: responsiveness to sub-micromolar calcium ionophore A23187
and phorbol esters. Biochim Biophys Acta 1994; 1223: 219–225.
19. Taimi M, Dornand J, Nicolas M, Marti J, Favero J. Involvement of CD4 in
interleukin-6  secretion  by  U937 monocytic  cells  stimulated  with  the
lectin jacalin. J Leukoc Biol 1994; 55: 214–20.
20. Paul-Eugene N, Amirand C, Ouaaz F, et al. Biochemical and functional
alterations induced by CD23 ligation in the human promonocytic cell
line U937. Immunology 1993; 80: 424–430.
21. Taimi M, Defacque H, Commes T , et al. Effect of retinoic acid and vitamin
D on the expression of interleukin-1 beta, tumour necrosis factor-alpha
and interleukin-6 in the human monocytic cell line U937. Immunology
1993; 79: 229–235.
22. Hass R, Lonnemann G, Mannel D, et al. Regulation of TNF-alpha, IL-1 and
IL-6  synthesis  in  differentiating  human  monoblastoid  leukemic  U937
cells. Leuk Res 1991; 15: 327–339.
23. Jiang WG, Puntis MC, Hallett MB. U937 cells stimulated with opsonised
zymozan  particles provide  a  convenient laboratory  source of tumour
necrosis factor alpha. J Immunol Methods 1992; 152: 201–207.
24. Bosco  MC,  Gusella  GL,  Espinoza-Delgado  I,  Longo  DL,  Varesio  L.
Interferon-gamma  upregulates interleukin-8 gene expression in human
monocytic cells by a posttranscriptional mechanism. Blood 1994; 83:
537–542.
25. Srivastava  MD,  Srivastava  R, Srivastava  BI.  Constitutive  production  of
interleukin-8 (IL-8) by normal and malignant human B-cells and other cell
types. Leuk Res 1993; 17: 1063–1069.
26. Moutabarrik A, Takahara  S,  Namiki  M,  et  al.  Effect  of  FK  506  and
cyclosporine on the expression of IL-6 and its receptor on stimulated
monocytes. Transplant Proc 1993; 25: 2320–2321.
27. Berger AE, Carter DB, Hankey SO, McEwan RN. Cytokine regulation of
the  interleukin-1  receptor  antagonist  protein  in  U937  cells.  Eur  J
Immunol 1993; 23: 39–45.
28. Kato K, Yokoi T, Takano N, et al. Detection by in situ hybridization and
phenotypic characterization of cells expressing IL-6 mRNA in human
stimulated blood. J Immunol 1990; 144: 1317–1322.
29. Nair APK,  Hanh  S, Banholzer  R, Jirsch  HH,  Moroni  C. Cyclosporin A
inhibits growth  of  autocrine  tumour  cell  lines  by  destabilizing  inter-
leukin-3 mRNA. Nature 1994; 369: 239–242.
30. Granelli-Piperno A, Keane M, Steinman RM. Evidence that cyclosporine
inhibits cell-mediated immunity primarily at the level of the T lympho-
cyte rather than the accessory cell. Transplantation 1988; 46 (2 Suppl):
53S–60S.
31. Mrowietz  U,  Sticherling  M,  Mielke  V,  Schroder  JM,  Christophers  E.
Neutrophil-activating  peptide  1/interleukin  8  mRNA  expression  and
protein  secretion  by  human  monocytes:  effect  of  cyclosporin  A.
Cytokine 1991; 3: 322–326.
32. Roth J, Goebeler M, Erpenstein U, Sorg C. Differential regulation of the
macrophage-specific surface antigen RM3/1 by cyclosporine, azathiopr-
ine, and dexamethasone. Transplantation 1994; 57: 127–133.
33. Pigatto  PD,  Bersani  L, Altomare  G,  Mozzanica  N,  Finzi A.  Effects  of
cyclosporin A  on  psoariatic  monocyte  functions  and  secretion.  Acta
Derm Venereol Suppl Stochk 1989; 146: 165–167.
34. Langadale LA, Maier  RV , Wilson L, Pohlman TH, Williams JG, Rice CL.
Liposome-encapsulated  hemoglobin  inhibits  tumor  necrosis  factor
release  from  rabbit  alveolar  macrophages  by  a  posttranscriptional
mechanism. J Leukoc Biol 1992; 52: 679–686.
35. Chiara MD, Bedoya F, Sobrino F. Cyclosporin A inhibits phorbol ester-
induced activation of superoxide production in resident mouse perito-
neal macrophages. Biochem J 1989; 264: 21–26.
36. Wenzel-Seifert  K,  Schachtele  C,  Hummel  R,  Grunbaum  L,  Seifert  R.
Evidence  that  inhibition  of  phorbol  ester-induced  superoxide  anion
formation  by  cyclosporin A  in  phagocytes  is  not  mediated  by  direct
inhibition of protein kinase C. Biochem Pharmacol 1994; 48: 859–864.
37. Tschaikowsky K. Protein kinase C inhibitors suppress LPS-induced TNF
production in  alveolar  macrophages and  in whole  blood: the  role of
encapsulation  into  liposomes.  Biochim  Biophys  Acta 1994;  1222:
113–121.
38. Fruman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and
immunosuppression. FASEB J 1994; 8: 391–400.
Received 30 August 99;
accepted 24 September 99
Cyclosporin and macrophage IL-6 synthesis
Mediators of Inflammation · Vol 8 · 1999 259